The corrected paper is linked to research on the nanoformulation of essential oils obtained from peppermint, Mentha piperita L., and rosemary, Rosmarinus officinalis L. Its title indicates a focus on antibacterial effects, placing the work at the intersection of microbiology, natural products, food nanotechnology, and nanobiotechnology. Essential oils are complex mixtures of volatile organic compounds produced by plants. Many contain molecules capable of disturbing microbial membranes, altering permeability, affecting cellular metabolism, or interfering with biochemical processes. Yet their direct use can be limited by volatility, poor water solubility, rapid evaporation, sensitivity to light and oxygen, and difficulty maintaining a consistent concentration. Nanoformulation is one strategy researchers use to package such hydrophobic compounds into nanoscale delivery systems, potentially changing how they disperse, remain stable, and interact with microbial cells.

The correction itself contains no antibacterial measurements, microorganism lists, formulation recipes, particle-size data, or toxicity results. It therefore cannot be used to conclude that the peppermint or rosemary preparations were more powerful than conventional antibiotics, effective against infections in people, or ready for use in food, medicine, or agriculture. Those questions would require examination of the original research article and independent validation. The notice serves a narrower but essential purpose: it ensures that the person officially responsible for correspondence is correctly named. In scientific publishing, even a seemingly small metadata error can create practical problems. Researchers attempting to reproduce an experiment may contact the wrong author, editors may direct post-publication queries incorrectly, and responsibility for clarifying technical details may become ambiguous.

The distinction between an author and a corresponding author is especially relevant in collaborative research. A paper can involve investigators from several departments, institutions, or scientific disciplines, with different contributors handling microbiological assays, plant science, formulation development, or data analysis. The corresponding author acts as the publication’s principal communication point, both during peer review and after publication. This role does not necessarily mean that the person performed every experiment or led every aspect of the project. It means that the journal records that author as the contact for formal correspondence. In the corrected notice, the affiliations span the Department of Microbiology at Ka.C., Islamic Azad University, the Department of Agronomy and Agroecology at Ur.C., Islamic Azad University, and the Department of Plant Protection at Urmia University, all in Iran. The correction assigns the contact role to Miandoab, whose listed affiliation is the Department of Agronomy and Agroecology.

The technical subject behind the paper reflects a growing effort to make plant-derived antimicrobials more controllable. In a conventional essential-oil preparation, the active molecules may separate from water or form uneven mixtures, making laboratory exposure difficult to standardize. A nanoscale carrier can help disperse oil components through an aqueous environment, increasing the interfacial area between the formulation and surrounding fluid. Depending on the carrier and manufacturing method, the system may also influence release kinetics: compounds can be released rapidly, gradually, or in response to environmental conditions. These properties matter in antibacterial testing because the measured effect depends not only on the chemical identity of an oil’s constituents but also on how much of each compound reaches the bacterial cell, how long it remains available, and whether the formulation itself changes contact with the cell envelope.

Peppermint and rosemary oils are chemically complex rather than single active ingredients. Their composition can vary with plant variety, geography, cultivation conditions, harvest timing, extraction method, and storage. That variability is one reason that antibacterial claims based on “essential oil” alone require careful characterization. A reproducible study generally needs to establish the composition of the oil, describe the formulation, measure relevant physical properties, and use controlled microbiological assays. Nanoformulation can improve dispersion, but it does not automatically guarantee greater antibacterial activity, safety, stability, or commercial value. Particle size, surface chemistry, encapsulation efficiency, loading capacity, release behavior, and interactions with growth media can all affect experimental outcomes. The correction does not alter or elaborate on any of those parameters, so the available notice should be understood as a publication-record update rather than a new technical report.

The article’s placement in International Microbiology and its association with subjects including antimicrobials, natural products, oils, food nanotechnology, nanomedicine and nanotoxicology, and nanobiotechnology illustrates how broadly such research can be relevant. Plant-based antimicrobial systems are being investigated for possible roles in food preservation, surface protection, agricultural disease management, and other applications. Each context presents different requirements. A formulation intended to inhibit bacteria on food must be assessed for sensory effects, migration, stability, and consumer safety. A medical application would require rigorous toxicology, pharmacology, and clinical testing. An agricultural use would raise questions about environmental persistence, effects on beneficial organisms, and field performance. None of those applications can be inferred from the correction, but they explain why accurate author contact information matters for researchers seeking clarification before interpreting or extending the work.

The correction was published as an open-access notice in volume 29 of International Microbiology, on page 729, and identifies the original article as having been published on 28 February 2026. Its formal wording is direct: the authors regret that Aramideh was mistakenly captured as the corresponding author, state that Miandoab is the correct corresponding author, and confirm that the original article has been corrected. Such notices are part of the normal mechanism by which journals maintain the accuracy of the scholarly record. They distinguish a factual amendment from a retraction, expression of concern, or correction to experimental data. Here, the scientific title and the subject of the study remain the same; what changes is the attribution of the communication role. For readers following research on essential-oil nanoformulations, the update provides a more reliable route to the investigators responsible for answering questions about the published work.

The episode also highlights a broader point about the infrastructure of science: credibility depends not only on striking results but on precise, traceable records. Names, affiliations, publication dates, identifiers, and contact details allow studies to be found, discussed, reproduced, and connected to later research. In this case, the correction preserves the visibility of a study investigating peppermint and rosemary oils while removing an error that could have redirected scholarly correspondence. It does not establish that nanoformulated oils can replace antibiotics, nor does it provide evidence for clinical efficacy. Instead, it ensures that future readers, editors, and researchers know whom the journal recognizes as the corresponding author. That modest clarification may not change the chemistry of an essential oil or the behavior of a nanoparticle, but it strengthens the chain of accountability on which experimental science depends.

At the crux of this landmark study lies the concept of a host-directed adjuvant. Rather than attacking bacteria directly, this innovative adjuvant modulates the host’s intracellular milieu to strip persisters of their protective shelter, thereby rendering them vulnerable to antibiotics. This paradigm shift capitalizes on the intimate interplay between pathogen and host, exploiting host mechanisms to dismantle bacterial dormancy and metabolic quiescence that typify persister states. The findings disrupt traditional antimicrobial approaches, suggesting that empowering the host immune and cellular machinery could circumvent the deadlock posed by bacterial persistence.

Intracellular bacterial persisters represent a stealthy cohort residing within host cells, often macrophages, where they adopt a dormant-like metabolic state impervious to antibiotic assault. Conventional antimicrobials predominantly target bacterial growth processes; however, persisters downregulate these activities, rendering antibiotics ineffective. This phenotypic heterogeneity within bacterial populations fuels recalcitrant infections and relapses post-therapy. Hence, strategies that coax these cells out of dormancy or otherwise sensitize them to antibiotics stand to significantly enhance treatment outcomes.

The host-directed adjuvant unveiled by Lu and colleagues operates by perturbing the intracellular environment to disrupt persister cell homeostasis. Mechanistically, it influences host cell signaling pathways and metabolic networks, which in turn modulate the intracellular niche. This ultimately breaks bacterial dormancy programs and heightens susceptibility to antibiotic eradication. Crucially, this approach does not rely on identifying new antibiotics but leverages existing drugs more effectively, addressing the critical bottleneck that is persister-mediated antibiotic tolerance.

Experimental evidence from their study demonstrates that treatment with the adjuvant causes a significant reduction in intracellular persister load when combined with standard antibiotics. Using sophisticated infection models, including primary human macrophages infected with clinically relevant intracellular pathogens, the researchers confirmed that the adjuvant enhances antibiotic potency. These findings were substantiated through quantitative assays measuring bacterial viability, metabolic activity, and transcriptional reprogramming. Collectively, the data establish proof-of-concept for a combinational therapeutic paradigm that melds host modulation with traditional antibiotics.

Perhaps the most compelling aspect of this research is the therapeutic potential it opens for chronic and relapsing infections caused by notoriously persistent pathogens like Mycobacterium tuberculosis, Salmonella enterica, and Listeria monocytogenes. These pathogens exploit intracellular persistence to withstand therapy, necessitating prolonged treatment durations and complicating eradication efforts. By reinstating antibiotic sensitivity within the host cellular environment, the study’s approach heralds a new frontier in curtailing disease burden, minimizing resistance emergence, and shortening treatment courses.

From a molecular perspective, the adjuvant instigates alterations in host cell iron metabolism, reactive oxygen species (ROS) production, and autophagy pathways — all critical determinants of intracellular pathogen control. By modulating iron availability, the adjuvant impacts bacterial metabolic processes dependent on this micronutrient. Enhanced ROS levels contribute to oxidative stress within persisters, weakening their defenses. Meanwhile, upregulated autophagic pathways promote bacterial degradation. This multifaceted host reprogramming orchestrates an inhospitable environment for persister survival, synergizing with antibiotic action.

Beyond its mechanistic elegance, the research underscores the translational viability of this host-targeted strategy. The adjuvant molecules identified exhibit favorable pharmacokinetic and safety profiles in preclinical models, a pivotal consideration for clinical deployment. Moreover, this approach circumvents classical resistance mechanisms since it does not exert direct selective pressure on bacteria. Consequently, it represents a durable adjunct to antibiotic therapy that can be adapted to diverse infectious contexts.

The implications of this study resonate profoundly in the era of escalating antimicrobial resistance (AMR), recognized as a global health crisis. Traditional antibiotic pipelines have stalled, and no new classes of antibiotics have entered the market recently with the capacity to eradicate persister cells. Host-directed interventions such as this adjuvant strategy provide a complementary path to revitalizing antimicrobial efficacy while preserving the microbiome and reducing collateral damage to beneficial flora.

While challenges remain, including the identification of optimal adjuvant candidates and disentangling complex host–pathogen interactions in varied infection niches, this pioneering research lays the groundwork for a novel class of therapeutics. Future investigations will likely focus on fine-tuning adjuvant formulations, exploring combinatorial regimens across pathogen species, and advancing toward clinical trials. As scientific understanding deepens, such approaches could redefine standard-of-care protocols and reshape infection management globally.

Critically, this work accentuates the necessity of interdisciplinarity in tackling persistent infections. The intersection of immunology, microbiology, pharmacology, and systems biology has been instrumental in deciphering the host-pathogen dynamics and fostering innovation in treatment design. Harnessing host biology as an ally in antimicrobial therapy exemplifies this integrative scientific mindset, offering renewed optimism in conquering stubborn intracellular infections.

Concurrently, this research invites a reconsideration of how we approach therapeutic resistance. By focusing on the host environment instead of solely targeting the microbe, scientists are challenging the dogma that resistance primarily emerges from bacterial genetics. Instead, phenotypic tolerance mechanisms, such as persistence, play an equal, if not more insidious role. Addressing these dimensions heralds a sophisticated evolution in antimicrobial strategies.

Technological advances underpinning this study, including high-resolution imaging, single-cell transcriptomics, and metabolomics, have enabled unprecedented insight into persister physiology and response to host-directed treatments. Such cutting-edge tools are indispensable for mapping the complex molecular choreography within infected cells. They not only unravel the biology of persistence but also accelerate identification of host targets amenable to intervention.

In summation, the discovery of a host-directed adjuvant capable of sensitizing intracellular bacterial persisters to antibiotics marks a paradigm shift in infection control. It transcends conventional antimicrobial limitations by mobilizing host cellular defenses and metabolic pathways, yielding a potent combinational approach to eradicate resilient bacterial reservoirs. This innovative study heralds a new dawn in combating chronic infectious diseases and antimicrobial resistance — a scientific breakthrough with profound implications for global health in the twenty-first century.

Subject of Research: Host-directed therapies targeting intracellular bacterial persisters to enhance antibiotic efficacy.

Article Title: A host-directed adjuvant sensitizes intracellular bacterial persisters to antibiotics.

Article References:
Lu, KY., Yang, X., Eldridge, M.J.G. et al. A host-directed adjuvant sensitizes intracellular bacterial persisters to antibiotics. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02124-2

Image Credits: AI Generated

Clostridioides difficile is primarily recognized for its role in antibiotic-associated diarrhea and colitis. This hazardous bacterium can produce toxins that disrupt gut homeostasis, leading to significant morbidity in affected individuals, particularly those with compromised immune systems or previous antibiotic treatments. Despite its notoriety, the underlying mechanisms that allow C. difficile to manipulate the host’s biological systems continue to be poorly understood, paving the way for studies like the one conducted by Fettucciari et al.

At the core of this research is the exploration of how C. difficile engages with the adenosine system, a network that plays a pivotal role in immune responses, inflammation, and cellular communication within the host. Adenosine is a nucleoside that influences numerous physiological processes, including vasodilation, neurotransmission, and immune modulation. When released during cellular injury or stress, adenosine triggers protective responses that can paradoxically facilitate the survival of pathogens.

In their study, the authors delve into the mechanisms by which C. difficile exploits adenosine signaling pathways. They present compelling evidence that this bacterium can manipulate the host’s adenosine levels to create a favorable microenvironment for its growth and persistence. This manipulation not only evades host immunity but also causes imbalances in the normal regulatory processes, underscoring the pathogen’s cunning nature.

The research highlights the role of specific adenosine receptors and their signaling cascades that are essential for maintaining homeostasis in the gastrointestinal tract. The authors utilized a variety of experimental models, including in vitro studies and animal models, to elucidate the interplay between C. difficile and the adenosine system, demonstrating how the bacterium influences these receptors in its favor.

Another critical aspect studied was the impact of C. difficile toxins on adenosine signaling. The toxins produced by this pathogen not only damage epithelial cells but also induce the release of adenosine triphosphate (ATP), which can be converted into adenosine. This local increase in adenosine amplifies the effects of immune modulation, allowing C. difficile to thrive amidst a weakened immune response. Such a dual strategy of toxicity and adenosine manipulation illustrates the complexity of host-pathogen interactions.

The findings of this study provide significant insights into the molecular dialogue between pathogens and their hosts. By unraveling the strategies employed by C. difficile to manipulate the adenosine system, researchers can identify potential therapeutic targets that could disrupt this interaction. Interventions aimed at modulating adenosine signaling may offer a novel approach to combat infections caused by this challenging pathogen.

Furthermore, this research draws attention to the broader implications of manipulating the adenosine system beyond C. difficile. Other pathogens may also exploit similar mechanisms to hijack host responses, highlighting the need for a deeper understanding of adenosine biology in infectious diseases. By comprehensively mapping these interactions, future studies could pave the way for innovative treatments that bolster the host’s defenses against a multitude of infections.

The authors conclude by urging the scientific community to focus on the therapeutic potential of targeting adenosine pathways as a means to treat C. difficile infections and potentially other related diseases. Such approaches could lead to the development of groundbreaking therapies that not only inhibit the pathogen but also restore homeostasis within the host.

In summary, the work by Fettucciari et al. provides a compelling narrative of how Clostridioides difficile interacts with the host through the adenosine system, turning the tide in its favor. Their findings encapsulate a significant leap toward understanding the complexity of host-pathogen interactions and open new avenues for therapeutic intervention against one of the most notorious pathogens in modern medicine.

Subject of Research:

The manipulation of the host adenosine system by Clostridioides difficile.

Article Title:

Clostridioides difficile meets the adenosine system: the art of manipulating host homeostasis.

Article References:

Fettucciari, K., Cari, L., Spaterna, A. et al. *Clostridioides difficile* meets the adenosine system: the art of manipulating host homeostasis. *J Biomed Sci* 32, 66 (2025). https://doi.org/10.1186/s12929-025-01160-8

Image Credits:

AI Generated

DOI:

Keywords:

Clostridioides difficile, adenosine, host-pathogen interactions, immune modulation, bacterial toxins.